دورية أكاديمية
Association between IgG responses against the nucleocapsid proteins of alphacoronaviruses and COVID-19 severity.
| العنوان: | Association between IgG responses against the nucleocapsid proteins of alphacoronaviruses and COVID-19 severity. |
|---|---|
| المؤلفون: | Nückel J; Children's Hospital, School of Medicine, Technische Universität München, Munich, Germany.; German Centre for Infection Research (DZIF) partner site Munich, Munich, Germany., Planatscher E; Children's Hospital, School of Medicine, Technische Universität München, Munich, Germany., Mohr AW; German Centre for Infection Research (DZIF) partner site Munich, Munich, Germany.; DZIF Research Group 'Host Control of Viral Latency and Reactivation', Department of Medicine III, Klinikum der Universität München, Munich, Germany., Deichl K; Children's Hospital, School of Medicine, Technische Universität München, Munich, Germany., Mijočević H; Institute of Virology, School of Medicine, Technische Universität München & Helmholtz Zentrum München, Munich, Germany., Feuerherd M; Institute of Virology, School of Medicine, Technische Universität München & Helmholtz Zentrum München, Munich, Germany., Wolff L; Institute of Virology, School of Medicine, Technische Universität München & Helmholtz Zentrum München, Munich, Germany., Erber J; Department of Internal Medicine II, University Hospital Rechts der Isar, School of Medicine, Technische Universität München, Munich, Germany., Schneider J; Department of Internal Medicine II, University Hospital Rechts der Isar, School of Medicine, Technische Universität München, Munich, Germany., Quante M; Department of Internal Medicine II, University Hospital Rechts der Isar, School of Medicine, Technische Universität München, Munich, Germany., Winter C; Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technische Universität München, Munich, Germany.; TranslaTUM, Center for Translational Cancer Research, Technische Universität München, Munich, Germany., Ruland J; Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technische Universität München, Munich, Germany.; TranslaTUM, Center for Translational Cancer Research, Technische Universität München, Munich, Germany.; German Centre for Infection Research (DZIF) partner site Munich, Munich, Germany., Hapfelmeier A; Institute of General Practice and Health Services Research & Institute for AI and Informatics in Medicine, School of Medicine, Technische Universität München, Munich, Germany., Hammerschmidt W; Research Unit Gene Vectors, Helmholtz Zentrum München, Munich, Germany., Moosmann A; German Centre for Infection Research (DZIF) partner site Munich, Munich, Germany.; DZIF Research Group 'Host Control of Viral Latency and Reactivation', Department of Medicine III, Klinikum der Universität München, Munich, Germany., Protzer U; German Centre for Infection Research (DZIF) partner site Munich, Munich, Germany.; Institute of Virology, School of Medicine, Technische Universität München & Helmholtz Zentrum München, Munich, Germany., Behrends U; Children's Hospital, School of Medicine, Technische Universität München, Munich, Germany.; German Centre for Infection Research (DZIF) partner site Munich, Munich, Germany.; Institute of Virology, School of Medicine, Technische Universität München & Helmholtz Zentrum München, Munich, Germany., Mautner J; Children's Hospital, School of Medicine, Technische Universität München, Munich, Germany.; German Centre for Infection Research (DZIF) partner site Munich, Munich, Germany.; Institute of Virology, School of Medicine, Technische Universität München & Helmholtz Zentrum München, Munich, Germany.; Research Unit Gene Vectors, Helmholtz Zentrum München, Munich, Germany. |
| المصدر: | Frontiers in immunology [Front Immunol] 2022 Sep 07; Vol. 13, pp. 889836. Date of Electronic Publication: 2022 Sep 07 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Alphacoronavirus* , COVID-19*, Antibodies, Viral ; Antigens, Viral ; Humans ; Immunoglobulin G ; Nucleocapsid Proteins ; Pandemics ; Proteome ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus |
| مستخلص: | Understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial to contain the COVID-19 pandemic. Using a multiplex approach, serum IgG responses against the whole SARS-CoV-2 proteome and the nucleocapsid proteins of endemic human coronaviruses (HCoVs) were measured in SARS-CoV-2-infected donors and healthy controls. COVID-19 severity strongly correlated with IgG responses against the nucleocapsid (N) of SARS-CoV-2 and possibly with the number of viral antigens targeted. Furthermore, a strong correlation between COVID-19 severity and serum responses against N of endemic alpha- but not betacoronaviruses was detected. This correlation was neither caused by cross-reactivity of antibodies, nor by a general boosting effect of SARS-CoV-2 infection on pre-existing humoral immunity. These findings raise the prospect of a potential disease progression marker for COVID-19 severity that allows for early stratification of infected individuals. Competing Interests: Author UP is receiving grants from Hoehnle AG, SCG Cell Therapy and VirBio and personal fees from Abbott, Abbvie, Arbutus, Gilead, GSK, J&J, Roche, Sanofi, Sobi and Vaccitech. UP is co-founder and shareholder of SCG Cell Therapy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Nückel, Planatscher, Mohr, Deichl, Mijočević, Feuerherd, Wolff, Erber, Schneider, Quante, Winter, Ruland, Hapfelmeier, Hammerschmidt, Moosmann, Protzer, Behrends and Mautner.) |
| References: | Nat Commun. 2021 Jan 4;12(1):6. (PMID: 33397903) PLoS One. 2007 Jul 04;2(7):e583. (PMID: 17611619) J Med Virol. 2021 Jan;93(1):311-322. (PMID: 32633840) ACS Cent Sci. 2020 Dec 23;6(12):2238-2249. (PMID: 33372199) Nature. 2020 Aug;584(7819):115-119. (PMID: 32454513) mSphere. 2021 Apr 28;6(2):. (PMID: 33910993) Lancet Reg Health Eur. 2021 Jul;6:100122. (PMID: 34027514) Cell. 2021 Apr 1;184(7):1858-1864.e10. (PMID: 33631096) Clin Infect Dis. 2021 Nov 2;73(9):e3066-e3073. (PMID: 33147319) mBio. 2020 Sep 25;11(5):. (PMID: 32978311) Clin Infect Dis. 2021 Apr 8;72(7):1291-1292. (PMID: 32445559) Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508) Viruses. 2020 Jun 10;12(6):. (PMID: 32532138) J Clin Virol. 2021 Jun;139:104847. (PMID: 33965698) Front Med (Lausanne). 2021 May 07;8:615099. (PMID: 34026773) N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) Cell Rep. 2021 Dec 28;37(13):110169. (PMID: 34932974) Mayo Clin Proc. 2020 Aug;95(8):1701-1703. (PMID: 32753142) Nat Rev Microbiol. 2021 Mar;19(3):155-170. (PMID: 33116300) Analyst. 2021 Jan 21;146(2):382-402. (PMID: 33410826) Nat Immunol. 2020 Oct;21(10):1293-1301. (PMID: 32807944) Malawi Med J. 2012 Sep;24(3):69-71. (PMID: 23638278) Clin Infect Dis. 2020 Jul 28;71(15):778-785. (PMID: 32198501) Nat Commun. 2021 Aug 6;12(1):4740. (PMID: 34362897) Cell Rep. 2021 May 25;35(8):109164. (PMID: 33991511) Sci Immunol. 2020 Dec 7;5(54):. (PMID: 33288645) Immunity. 2020 Sep 15;53(3):524-532.e4. (PMID: 32783920) Science. 2020 Nov 27;370(6520):. (PMID: 32994364) EBioMedicine. 2021 Jun;68:103401. (PMID: 34051441) J Infect. 2015 Nov;71(5):599-602. (PMID: 26165609) mSphere. 2021 Mar 10;6(2):. (PMID: 33692194) N Engl J Med. 2020 Oct 29;383(18):1757-1766. (PMID: 32329974) Emerg Microbes Infect. 2020 Dec;9(1):1664-1670. (PMID: 32618497) Science. 2020 Oct 23;370(6515):. (PMID: 32972996) Front Immunol. 2020 Dec 18;11:610688. (PMID: 33391281) Nat Commun. 2020 Jul 14;11(1):3581. (PMID: 32665645) Life (Basel). 2021 Apr 01;11(4):. (PMID: 33915711) Clin Vaccine Immunol. 2010 Dec;17(12):1875-80. (PMID: 20943876) Clin Immunol. 2020 Jun;215:108427. (PMID: 32325252) Sci Rep. 2019 Feb 4;9(1):1390. (PMID: 30718599) Lancet Infect Dis. 2020 May;20(5):565-574. (PMID: 32213337) Diagnostics (Basel). 2021 Jan 06;11(1):. (PMID: 33418886) J Med Virol. 2021 May;93(5):3211-3218. (PMID: 33620098) J Lab Clin Med. 1988 Nov;112(5):634-40. (PMID: 3183495) Nat Commun. 2020 Sep 17;11(1):4704. (PMID: 32943637) J Clin Microbiol. 2020 May 26;58(6):. (PMID: 32245835) Sci Transl Med. 2020 Jun 3;12(546):. (PMID: 32493791) Euro Surveill. 2021 Apr;26(13):. (PMID: 33797390) PLoS One. 2020 Nov 17;15(11):e0241955. (PMID: 33201896) |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2; coronavirus; multiplex serology; nucleocapsid protein |
| المشرفين على المادة: | 0 (Antibodies, Viral) 0 (Antigens, Viral) 0 (Immunoglobulin G) 0 (Nucleocapsid Proteins) 0 (Proteome) 0 (Spike Glycoprotein, Coronavirus) 0 (spike protein, SARS-CoV-2) |
| تواريخ الأحداث: | Date Created: 20220926 Date Completed: 20220928 Latest Revision: 20220928 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC9490404 |
| DOI: | 10.3389/fimmu.2022.889836 |
| PMID: | 36159804 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!